CD274 and non-small cell lung carcinoma: The KEYNOTE-024 study analyzing the efficacy of immunotherapy in the first line of treatment for advanced non-small-cell lung cancer with PD-L1 expression on at least 50% of cells confirmed a significant prolongation of overall survival (OS) compared with the group of patients treated with standard platinum-based chemotherapy (30.0 months vs. 14.2 months) [63].